We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

40 hedge funds and large institutions have $7.28M invested in BioXcel Therapeutics in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

28% more capital invested

Capital invested by funds: $5.66M → $7.28M (+$1.61M)

8.71% more ownership

Funds ownership: 16.17% → 24.88% (+8.7%)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

2% less funds holding

Funds holding: 41 → 40 (-1)

Holders
40
Holders Change
-1
Holders Change %
-2.44%
% of All Funds
0.49%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
9
Reduced
7
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
AC
Armistice Capital
New York
+$3.15M
2
Millennium Management
Millennium Management
New York
+$167K
3
P
&Partners
Tennessee
+$133K
4
Man Group
Man Group
United Kingdom
+$65.3K
5
State Street
State Street
Massachusetts
+$47.6K

Top Sellers

1
Jane Street
Jane Street
New York
-$204K
2
GCP
GSA Capital Partners
United Kingdom
-$192K
3
HF
HRT Financial
New York
-$28K
4
TSS
Two Sigma Securities
New York
-$27.3K
5
EGM
Engineers Gate Manager
New York
-$19.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
SGFG
26
Silver Grove Financial Group
New York
$447 +$550 +334 New
WTA
27
Washington Trust Advisors
Massachusetts
$214 – – –
AGWCA
28
Annis Gardner Whiting Capital Advisors
Florida
$210 +$72 +44 +39%
PFBT
29
Parkside Financial Bank & Trust
Missouri
$151 – – –
EWA
30
EverSource Wealth Advisors
Alabama
$80 – – –
BNP Paribas Financial Markets
31
BNP Paribas Financial Markets
France
$79 +$77 +47 +392%
JP Morgan Chase
32
JP Morgan Chase
New York
$54 – – –
FFA
33
Farther Finance Advisors
California
$31 – – –
Northwestern Mutual Wealth Management
34
Northwestern Mutual Wealth Management
Wisconsin
$28 – – –
SS
35
SBI Securities
Japan
$19 -$255 -155 -92%
IA
36
IFP Advisors
Florida
$17 -$7.18K -4,357 -100%
Zurich Cantonal Bank
37
Zurich Cantonal Bank
Switzerland
$3 – – –
Group One Trading
38
Group One Trading
Illinois
$1 -$5.24K -3,184 -100%
TCM
39
Triumph Capital Management
Colorado
$1 – – –
US Bancorp
40
US Bancorp
Minnesota
$1 – – –
Jane Street
41
Jane Street
New York
– -$204K -127,501 Closed
GCP
42
GSA Capital Partners
United Kingdom
– -$192K -120,102 Closed
HF
43
HRT Financial
New York
– -$28K -18,062 Closed
TSS
44
Two Sigma Securities
New York
– -$27.3K -17,068 Closed
EGM
45
Engineers Gate Manager
New York
– -$19.7K -12,303 Closed
Citigroup
46
Citigroup
New York
– -$19.3K -12,079 Closed
CIAM
47
Caitong International Asset Management
Hong Kong
– -$2.63K -1,642 Closed
Bank of America
48
Bank of America
North Carolina
– -$2.31K -1,446 Closed
1
2

BTAI Hedge Fund Activity: Q1 2026 in Review

40 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2026, worth a combined $7.28M — up 28% from $5.66M a quarter earlier.

Fund positioning in BTAI was balanced in Q1 2026: 8 funds opened new positions, 8 closed out, 9 added to existing stakes and 7 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $3.15M. The largest seller was Jane Street, exiting entirely with an estimated $204K sold.

  • 40 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2026, down from 41 in Q4 2025.
  • Funds reported $7.28M of BioXcel Therapeutics stock for Q1 2026, up 28% quarter-over-quarter.
  • 8 funds opened new BioXcel Therapeutics positions in Q1 2026 and 8 closed out, a net change of 0 holders.
  • The largest BioXcel Therapeutics buyer in Q1 2026 was Armistice Capital, an estimated $3.15M added.
  • The largest BioXcel Therapeutics seller in Q1 2026 was Jane Street, an estimated $204K sold.

Based on aggregated 13F filings for Q1 2026.